A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
In her 2008 book The How of Happiness, Sonja Lyubomirsky similarly argued people's happiness varies around a genetic set point. Diener warns, however, that it is nonsensical to claim that "happiness is influenced 30–50% by genetics". Diener explains that the recipe for happiness for an individual always requires genetics, environment, and behaviour too, so it is nonsensical to claim that an individual's happiness is due to only one ingredient. Only differences in happiness can be attributed to differences in factors. In other words, Lyubomirsky's research does not discuss happiness in one individual; it discusses differences in happiness between two or more people. Specifically, Lyubomirsky suggests that 30–40% of the difference in happiness levels is due to genetics (i.e. heritable). In other words, still, Diener says it makes no sense to say one person's happiness is "due 50% to genetics", but it does make sense to say one person's difference in happiness is 50% due to differences in their genetics (and the rest is due to behaviour and environment). Findings from twin studies support the findings just mentioned. Twins reared apart had nearly the same levels of happiness thereby suggesting the environment is not entirely responsible for differences in people's happiness. Importantly, an individual's baseline happiness is not entirely determined by genetics, and not even by early life influences on one's genetics.
== Emitters == Several different emitter configurations have been used for FD emitters, such as single tips, sharp blades and thin wires. Single metal tips can be made from etching wires either by periodically dipping them into molten salts or by electrolysis in aqueous solutions. Compared to other emitter types, the single tips have the advantage that they can reach the highest field strengths. In addition, well-defined geometric shape of a single tip allows accurate calculation of the potential distribution in the space between the tip and the counter electrode. For blades used as emitters, their ruggedness under the high electric field is one of their advantages. Different thin wires were also used as emitters, such as platinum wires and tungsten wires. Platinum wires are fragile, and tungsten wires are much more stable than platinum wires. Among those emitters, carbon-microneedles tungsten wires are the most widely used emitters in FD mass spectrometry.
== Diagnosis == A combination of physical examination of the arch and plantar fascia, as well as ultrasound imaging by a physician is the usual path to diagnosis. An MRI (Magnetic Resonance Imaging) scan is usually the imaging of choice to determine between other possible conditions such as ganglion cysts. MRI tends to be more accurate than x-ray or ultrasound, showing the full extent of the condition.
Due to its extremely long half-life, 209Bi can be treated as non-radioactive for nearly all applications. It is much less radioactive than human flesh, so it poses no real radiation hazard. Though 209Bi holds the half-life record for alpha decay, it does not have the longest known half-life of any nuclide; this distinction belongs to tellurium-128 (128Te) with a half-life estimated at 7.7×1024 years by double beta decay. The half-life of 209Bi was confirmed in 2012 by an Italian team in Gran Sasso who reported (2.01±0.08)×1019 years. They also reported an even longer partial half-life for alpha decay of 209Bi to the first excited state of 205Tl (at 204 keV), estimated at 1.66×1021 years. Even though this value is shorter than the half-life of 128Te, both alpha decays of 209Bi hold the record of the thinnest natural line widths of any measurable physical excitation, estimated respectively at ΔΕ ≈ 5.5×10−43 eV and ΔΕ ≈ 1.3×10−44 eV in application of the uncertainty principle
Sources: en.wikipedia.org
== Further reading == Wolfram-Schauerte, Maik; Pozhydaieva, Nadiia; Grawenhoff, Julia; Welp, Luisa M.; Silbern, Ivan; Wulf, Alexander; Billau, Franziska A.; Glatter, Timo; Urlaub, Henning; Jäschke, Andres; Höfer, Katharina (August 16, 2023). "A viral ADP-ribosyltransferase attaches RNA chains to host proteins". Nature. 620 (7976): 1054–1062. Bibcode:2023Natur.620.1054W. doi:10.1038/s41586-023-06429-2. PMC 10468400. PMID 37587340.
UHDTV potentially allows Rec. 2020, higher dynamic range, and higher frame rates to work on HD services without increasing resolution to 4K, providing improved quality without as high of an increase in bandwidth demand.
=== Aviation and spaceflight === Barotrauma caused during airplane journeys is also referred to as airplane ear. The environmental pressure must be prevented from changing rapidly by large amounts. One should include multiple redundant levels of protection against rapid decompression, and systems allowing non-catastrophic failure with sufficient time to allow comfortable equalization of relevant air spaces, particularly the inner ear. A low internal pressure reduces decompression rate and severity in a catastrophic decompression reduces the risk of barotrauma but can increase the risk of decompression sickness and hypoxia in normal operating conditions. Some measures for protection against rapid decompression specific to airplanes include:
== Signs and symptoms == Generally, fractures are a result of traumatic injury, underlying pathology, or overuse. Fractures are painful though there are no pain receptors in the bone. This is a result of damage to the periosteum and endosteum, hematoma formation, soft tissue injury, and contraction of nearby muscle groups in response to disturbed anatomy. Physical signs include obvious deformity, inability to bear weight or use the limb, bruising, and swelling.
=== In other animals === Lingual lipase – Rats and mice secrete a type of lipase (fat-digesting enzyme) from the Von Ebner's glands which are located at the back of the tongue. The analogous enzyme in humans is secreted in the stomach and called gastric lipase (LIPF).
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.